ObsEva Stock Price Target and Analyst Ratings (NASDAQ:OBSV)

Analyst Price Target for OBSV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$11.80

▲ +266.46% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $11.80, with a high forecast of $28.00 and a low forecast of $4.00. The average price target represents a 266.46% upside from the last price of $3.22.

Hold

The current consensus among 5 investment analysts is to hold stock in ObsEva. This rating has held steady since December 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/14/2019

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/13/2019

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/12/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/10/2020

0 strong buy ratings
4 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

9/8/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/7/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

2/5/2021

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/7/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/12/2021	Wedbush	Reiterated Rating	Buy	$28.00	Low	i Rating by Liana Moussatos at Wedbush
1/12/2021	SVB Leerink	Boost Price Target	Outperform	$4.00 ➝ $5.00	Low	i
1/4/2021	HC Wainwright	Lower Price Target	Buy	$23.00 ➝ $17.00	N/A	i
11/9/2020	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Medium	i
10/5/2020	HC Wainwright	Lower Price Target	Buy	$36.00 ➝ $23.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/14/2020	Wedbush	Reiterated Rating	Buy	$30.00	High	i Rating by Liana Moussatos at Wedbush
7/7/2020	SVB Leerink	Lower Price Target	Outperform	$7.00 ➝ $5.00	High	i
7/7/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$18.00 ➝ $5.00	High	i
7/6/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$5.00 ➝ $4.00	High	i
7/1/2020	HC Wainwright	Reiterated Rating	Buy	$36.00	Low	i Rating by Ram Selvaraju at HC Wainwright
7/1/2020	Wedbush	Reiterated Rating	Buy	$30.00	Low	i Rating by Liana Moussatos at Wedbush
6/5/2020	HC Wainwright	Reiterated Rating	Buy	$36.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/5/2020	Wedbush	Reiterated Rating	Buy	$30.00	High	i Rating by Liana Moussatos at Wedbush
3/23/2020	Wedbush	Reiterated Rating	Buy	$40.00 ➝ $34.00	Medium	i Rating by Liana Moussatos at Wedbush
3/23/2020	HC Wainwright	Lower Price Target	Buy	$40.00 ➝ $36.00	Low	i Rating by Ram Selvaraju at HC Wainwright
3/5/2020	Wedbush	Boost Price Target	Outperform	$36.00 ➝ $40.00	High	i Rating by Liana Moussatos at Wedbush
1/21/2020	Wedbush	Reiterated Rating	Buy	$36.00	High	i Rating by Liana Moussatos at Wedbush
1/21/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	High	i Rating by Ram Selvaraju at HC Wainwright
12/19/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $40.00	High	i Rating by Ram Selvaraju at HC Wainwright
12/10/2019	Royal Bank of Canada	Boost Price Target	Outperform	$18.00 ➝ $19.00	High	i
12/2/2019	HC Wainwright	Reiterated Rating	Buy	$44.00 ➝ $36.00	Low	i Rating by Ram Selvaraju at HC Wainwright
11/8/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$16.00 ➝ $4.00	High	i
10/31/2019	Wedbush	Reiterated Rating	Buy	$38.00	Medium	i Rating by Liana Moussatos at Wedbush
10/11/2019	Wedbush	Set Price Target	Buy	$38.00	Low	i Rating by Liana Moussatos at Wedbush
9/4/2019	HC Wainwright	Reiterated Rating	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
8/11/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low	i
7/29/2019	Credit Suisse Group	Lower Price Target	Outperform	$24.00 ➝ $16.00	Medium	i
7/18/2019	Wedbush	Reiterated Rating	Outperform	$38.00	High	i Rating by Liana Moussatos at Wedbush
7/8/2019	Wedbush	Set Price Target	Buy	$38.00	Low	i Rating by Liana Moussatos at Wedbush
6/19/2019	Wedbush	Reiterated Rating	Buy	$38.00	Medium	i Rating by Liana Moussatos at Wedbush
6/5/2019	HC Wainwright	Set Price Target	Buy	$44.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
5/28/2019	HC Wainwright	Reiterated Rating	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
5/10/2019	Wedbush	Set Price Target	Buy	$38.00	Medium	i Rating by Liana Moussatos at Wedbush
5/6/2019	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by Ram Selvaraju at HC Wainwright
4/29/2019	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by Ram Selvaraju at HC Wainwright
3/7/2019	HC Wainwright	Set Price Target	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
1/25/2019	Wedbush	Set Price Target	Buy	$34.00	High	i Rating by Liana Moussatos at Wedbush
1/23/2019	HC Wainwright	Set Price Target	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
1/15/2019	Wedbush	Set Price Target	Buy	$34.00	High	i Rating by Liana Moussatos at Wedbush
1/4/2019	HC Wainwright	Set Price Target	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
12/11/2018	Wedbush	Reiterated Rating	Buy	$34.00	Low	i Rating by Liana Moussatos at Wedbush
12/10/2018	HC Wainwright	Reiterated Rating	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
10/15/2018	HC Wainwright	Set Price Target	Buy	$44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
10/3/2018	Wedbush	Set Price Target	Buy	$34.00	High	i Rating by Liana Moussatos at Wedbush
9/13/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$29.00	Low	i
8/29/2018	HC Wainwright	Set Price Target	Buy	$44.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/15/2018	SVB Leerink	Initiated Coverage	Outperform	$25.00	Low	i Rating by A. Fadia at SVB Leerink LLC
8/8/2018	HC Wainwright	Set Price Target	Buy	$44.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/6/2018	Wedbush	Initiated Coverage	Outperform	$34.00	High	i Rating by L. Moussatos at Wedbush
7/25/2018	HC Wainwright	Set Price Target	Buy	$30.00	Low	i Rating by Ram Selvaraju at HC Wainwright
7/19/2018	Credit Suisse Group	Initiated Coverage	Outperform	$24.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
7/16/2018	HC Wainwright	Set Price Target	Buy	$30.00	High	i Rating by Ram Selvaraju at HC Wainwright
6/18/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$23.00 ➝ $31.00	High	i
6/12/2018	BMO Capital Markets	Initiated Coverage	Outperform	$23.00	High	i
6/11/2018	HC Wainwright	Set Price Target	Buy	$28.00	Low	i Rating by Ram Selvaraju at HC Wainwright
5/29/2018	HC Wainwright	Reiterated Rating	Buy	$28.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
3/9/2018	HC Wainwright	Reiterated Rating	Buy	$27.00	Low	i Rating by Ram Selvaraju at HC Wainwright
2/27/2018	BMO Capital Markets	Reiterated Rating	Buy	$24.00	High	i
2/27/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00	High	i
2/27/2018	Credit Suisse Group	Reiterated Rating	Outperform ➝ Buy	$16.00 ➝ $18.00	Low	i
2/5/2018	HC Wainwright	Reiterated Rating	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
1/4/2018	HC Wainwright	Set Price Target	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
12/14/2017	HC Wainwright	Set Price Target	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
12/4/2017	BMO Capital Markets	Initiated Coverage	Outperform	$20.00	Low	i
11/29/2017	HC Wainwright	Set Price Target	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
11/8/2017	HC Wainwright	Reiterated Rating	Buy	$25.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
11/2/2017	Royal Bank of Canada	Reiterated Rating	Buy	$22.00	N/A	i
10/30/2017	HC Wainwright	Set Price Target	Buy	$25.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
10/11/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $25.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
10/9/2017	Credit Suisse Group	Initiated Coverage	Outperform	$27.00 ➝ $16.00	N/A	i
10/4/2017	HC Wainwright	Reiterated Rating	Buy	$27.00	High	i Rating by Ram Selvaraju at HC Wainwright
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$22.00	Low	i
9/8/2017	HC Wainwright	Reiterated Rating	Buy	$27.00	Low	i Rating by Ram Selvaraju at HC Wainwright
8/16/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$18.00	High	i Rating by J. Gerberry at SVB Leerink LLC
8/16/2017	HC Wainwright	Set Price Target	Buy	$27.00	Low	i Rating by Ram Selvaraju at HC Wainwright
6/29/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$27.00	High	i
4/18/2017	Credit Suisse Group	Reiterated Rating	Outperform	$27.00	Low	i
2/21/2017	SVB Leerink	Initiated Coverage	Outperform	$21.00	N/A	i Rating by J. Gerberry at SVB Leerink LLC
2/21/2017	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$27.00	N/A	i
2/21/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$21.00	N/A	i

(Data available from 3/7/2016 forward)

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Today's Range

Now: $3.22

$2.85

$3.48

50 Day Range

MA: $3.99

$2.52

$5.05

52 Week Range

Now: $3.22

$1.63

$6.30

Volume

3,334,881 shs

Average Volume

8,352,549 shs

Market Capitalization

$154.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

The following Wall Street sell-side analysts have issued reports on ObsEva in the last year: BMO Capital Markets, HC Wainwright, JPMorgan Chase & Co., SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for OBSV.

What is the current price target for ObsEva?

5 Wall Street analysts have set twelve-month price targets for ObsEva in the last year. Their average twelve-month price target is $11.80, suggesting a possible upside of 266.5%. Wedbush has the highest price target set, predicting OBSV will reach $28.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $4.00 for ObsEva in the next year.
View the latest price targets for OBSV.

What is the current consensus analyst rating for ObsEva?

ObsEva currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OBSV, but not buy more shares or sell existing shares.
View the latest ratings for OBSV.

What other companies compete with ObsEva?

Other companies that are similar to ObsEva include BELLUS Health, Ardelyx, Akouos, Inventiva, Clovis Oncology, Chimerix, IDEAYA Biosciences, Flexion Therapeutics, Eagle Pharmaceuticals, Geron, Relmada Therapeutics, Molecular Templates, KalVista Pharmaceuticals, XBiotech and IVERIC bio.

How do I contact ObsEva's investor relations team?

ObsEva's physical mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company's listed phone number is 41-22-552-3840 and its investor relations email address is [email protected] The official website for ObsEva is www.obseva.com.

NASDAQ:OBSV - ObsEva Stock Price Target and Predictions

Analyst Price Target for OBSV

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

What is the current price target for ObsEva?

What is the current consensus analyst rating for ObsEva?

What other companies compete with ObsEva?

How do I contact ObsEva's investor relations team?